Sarah Gordon-Wild
Direttore/Membro del Consiglio presso Leweston School
Patrimonio netto: 386 188 $ in data 31/05/2024
Posizioni attive di Sarah Gordon-Wild
Società | Posizione | Inizio | Fine |
---|---|---|---|
Hy. Duke & Son Ltd.
Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Corporate Officer/Principal | - | - |
Direttore/Membro del Consiglio | - | - | |
Leweston School | Direttore/Membro del Consiglio | - | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | - | - |
Larkham Ltd. | Direttore/Membro del Consiglio | - | - |
Sgw Research Ltd. | Direttore/Membro del Consiglio | - | - |
The Bridport Literary Festival Ltd. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Sarah Gordon-Wild
Precedenti posizioni note di Sarah Gordon-Wild
Società | Posizione | Inizio | Fine |
---|---|---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Direttore/Membro del Consiglio | 01/01/2015 | 19/12/2023 |
REDX PHARMA PLC | Direttore/Membro del Consiglio | 01/07/2020 | 30/09/2023 |
Independent Dir/Board Member | 01/07/2020 | 30/09/2023 | |
Lone Pine Capital (UK) Ltd.
Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Amministratore Delegato | 01/01/1998 | 01/01/2003 |
Formazione di Sarah Gordon-Wild
Imperial College London | Graduate Degree |
University of Aberdeen | Undergraduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 12 |
Posizioni
Director/Board Member | 8 |
Corporate Officer/Principal | 1 |
Independent Dir/Board Member | 1 |
Settori
Consumer Services | 3 |
Health Technology | 3 |
Electronic Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Technology |
REDX PHARMA PLC | Health Technology |
Aziende private | 7 |
---|---|
Lone Pine Capital (UK) Ltd.
Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Finance |
Hy. Duke & Son Ltd.
Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Retail Trade |
Leweston School | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Larkham Ltd. | |
Sgw Research Ltd. | |
The Bridport Literary Festival Ltd. |
- Borsa valori
- Insiders
- Sarah Gordon-Wild
- Esperienza